カテゴリ： GlobalData, アメリカ, 企業調査

Aeglea BioTherapeutics Inc (AGLE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8297
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：57
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company’s product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Venture Financing 12
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Partnerships 16
Aeglea BioTherapeutics Enters into Agreement with Merck 16
Licensing Agreements 17
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
Equity Offering 18
Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18
Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20
Aeglea BioTherapeutics Raises USD54.8 million in IPO 21
Aeglea BioTherapeutics Inc – Key Competitors 22
Aeglea BioTherapeutics Inc – Key Employees 23
Aeglea BioTherapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Aeglea Biotherapeutics provides corporate update and reports second quarter 2018 financial results 25
May 08, 2018: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results 27
Mar 13, 2018: Aeglea BioTherapeutics Reports Q4 and Full Year 2017 Financial Results 29
Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30
Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 31
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 32
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 35
Jul 16, 2018: Aeglea BioTherapeutics names Dr. Bryan Lawlis as board director 35
Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 36
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 37
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 38
Product News 39
11/29/2017: Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102) 39
09/06/2017: Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency 40
05/23/2017: Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update 41
04/03/2018: Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting 43
03/26/2018: Aeglea BioTherapeutics Appoints Dr. Ivana Magovcevic-Liebisch to Board of Directors 44
03/13/2018: Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency 45
03/06/2018: Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders 47
02/28/2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism 48
Clinical Trials 49
Apr 05, 2018: Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting 49
Apr 02, 2018: Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination Trials 50
Mar 08, 2018: Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase 51
Jan 18, 2018: Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference 52
Nov 02, 2017: Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting 53
Mar 29, 2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting 54
Mar 23, 2017: Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting 55
Jan 17, 2017: Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Aeglea BioTherapeutics Enters into Agreement with Merck 16
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18
Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20
Aeglea BioTherapeutics Raises USD54.8 million in IPO 21
Aeglea BioTherapeutics Inc, Key Competitors 22
Aeglea BioTherapeutics Inc, Key Employees 23
Aeglea BioTherapeutics Inc, Subsidiaries 24

List of Figures
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aeglea BioTherapeutics Inc (AGLE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Defense Commissary Agency：企業の戦略的SWOT分析
    Defense Commissary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Broncus Medical Inc-医療機器分野：企業M&A・提携分析
    Summary Broncus Medical Inc (Broncus), formerly Broncus Technologies Inc is a medical device company that develops navigation, diagnostic and therapeutic technologies. The company’s products comprise lungpoint virtual bronchoscopic navigation system, lungpoint satellite planning system, and flexneed …
  • Lakeland Financial Corporation：企業の戦略・SWOT・財務情報
    Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report Summary Lakeland Financial Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Graham Holdings Company (GHC)：企業の財務・戦略的SWOT分析
    Graham Holdings Company (GHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • OGK-2 (OGKB)：企業の財務・戦略的SWOT分析
    OGK-2 (OGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Genera Biosystems Ltd (GBI)-製薬・医療分野：企業M&A・提携分析
    Summary Genera Biosystems Ltd (GBL) is a developer and commercializer of multiplexed molecular diagnostic testing products. The company offers RTIplex and PapType molecular diagnostic test. Its RTIplex is a multiplexed and automated PCR based test for detection of viral and bacterial respiratory pat …
  • Elk Petroleum Ltd (ELK)：石油・ガス：M&Aディール及び事業提携情報
    Summary Elk Petroleum Ltd (Elk) is an oil and gas company that explore, produce, and develops oil and gas properties. The company operates projects in Grieve oil field and Singleton oil field. Its Grieve oil field development project is a joint venture between the company and Denbury Resources, a pe …
  • Universal Display Corp (OLED)：企業の財務・戦略的SWOT分析
    Summary Universal Display Corp (UDC) is a clean technology company that conducts research, develops and markets organic light emitting diode, technologies and materials. The company offers PHOLED materials which are used in making OLED displays and lighting panels. It provides technologies such as F …
  • PLx Pharma Inc (PLXP)：製薬・医療：M&Aディール及び事業提携情報
    Summary PLx Pharma Inc (PLx Pharma) is a pharmaceutical company that develops patent-protected delivery systems. The company offers products such as PLxGuard delivery system, PLxGuard pipeline products, and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of …
  • Japan Wind Development Co Ltd：電力：M&Aディール及び事業提携情報
    Summary Japan Wind Development Co Ltd (JWD) is a renewable energy company that operates and develops wind power generation plants. The company offers operation and maintenance, construction and development of wind power plants. It also develops green power system integration technology. JWD’s power …
  • Novartis India Ltd (500672)：企業の財務・戦略的SWOT分析
    Summary Novartis India Ltd (Novartis), a subsidiary of Novartis AG, is a healthcare company that offers pharmaceuticals, generic medicine and eye care products. The company’s pharmaceutical division develops drugs in the therapeutic areas of bone and pain, calcium portfolio, gynecology, oncology and …
  • Showa Denko KK (4004)：企業の財務・戦略的SWOT分析
    Showa Denko KK (4004) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • BankAxept AS：企業の戦略・SWOT・財務情報
    BankAxept AS - Strategy, SWOT and Corporate Finance Report Summary BankAxept AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dampier Gold Limited：企業の戦略・SWOT・財務分析
    Dampier Gold Limited - Strategy, SWOT and Corporate Finance Report Summary Dampier Gold Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Shanghai Zhenhua Heavy Industry Co Ltd：戦略・SWOT・企業財務分析
    Shanghai Zhenhua Heavy Industry Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Zhenhua Heavy Industry Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Rubicon Genomics Inc-製薬・医療分野：企業M&A・提携分析
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • Scomi Group Bhd (SCOMI)：企業の財務・戦略的SWOT分析
    Scomi Group Bhd (SCOMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • BioCision LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary BioCision LLC (BioCision) is a life science research and development company that develops products and solutions for process standardization. The company provides products such as cell cryopreservation systems, ice-free cooling systems, tube and plate temperature management systems, cell th …
  • Theraclone Sciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Theraclone Sciences Inc (Theraclone) is a biotech company that develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company offers development programs on infectious disease which include novel antibodies to fight pandemic and seasonal influenza. It …
  • Kenra Professional, LLC：企業の戦略・SWOT・財務情報
    Kenra Professional, LLC - Strategy, SWOT and Corporate Finance Report Summary Kenra Professional, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆